Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs

Eissa, Sanaa; Kassim, Samar K.; Labib, Randa; El-Khouly, Inas M.; Ghaffer, Taghreed M.; Sadek, Mohamed; Razek, Omar Abdel; el-Ahmady, O

doi:10.1002/cncr.20902

Cited by 53 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conventional RT-PCR for detection of CK20 mRNA Detection of CK20 by RT-PCR was done in urine and optimized as previously described [14]: 2 lg of total RNA was subjected to first-strand cDNA synthesis using Maloney murine leukemia virus (MMV) reverse transcriptase and oligo primer pd (T) [12][13][14][15][16][17][18] for 1 h at 42°C. RT-PCR was performed using the Ready-to-Go TM RT-PCR Beads (0.2 ml tubes) (Amersham Pharmacia Biotech, Piscataway NJ).…”

Section: Rna Extractionmentioning

confidence: 99%

The clinical relevance of urine-based markers for diagnosis of bladder cancer

Eissa

Swellam²,

Amin

et al. 2011

Med Oncol

Self Cite

View full text Add to dashboard Cite

The aim of the present study was to evaluate the diagnostic relevance of urinary fibronectin (FN), telomerase (RTA), and cytokeratin 20 (CK20) mRNA in comparison with voided urine cytology (VUC). The study included 132 patients with bladder cancer, 60 patients with benign bladder lesions, and 48 healthy individuals. All were subjected to urine cytology, estimation of fibronectin by ELISA, RTA by TRAP, and CK20 mRNA by conventional RT-PCR in urothelial cells from voided urine. The best cutoff point for FN was determined by receiver operating characteristic curve (41.7 ng/mg protein) revealed the highest sensitivity for malignant (80%) followed by the benign (70%) than the healthy individuals (4.1%) at P < 0.001. Also, RTA and VUC showed significant difference among the three investigated groups (P < 0.001). The overall sensitivity (89.3%) and specificity (98.4%) were the highest for CK20 mRNA. Combined sensitivity of VUC with FN, RTA, and CK20 mRNA together (98.4%) was higher than either the combined sensitivity of VUC with any of them or than that of the biomarker alone. Accordingly, when the diagnostic efficacy was considered, CK20 mRNA had the highest sensitivity and specificity compared to all investigated markers.

show abstract

Section: Rna Extractionmentioning

confidence: 99%

The clinical relevance of urine-based markers for diagnosis of bladder cancer

Eissa

Swellam²,

Amin

et al. 2011

Med Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The increased hyaluronidase levels in bladder cancer patients are due to increased HYAL1 expression in bladder tumor cells both at the transcriptional and protein levels (16)(17)(18). HYAL1 expression is a potential prognostic indicator for prostate cancer progression and a possible marker for detecting head and neck squamous cell carcinoma (19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

HYAL1-v1, An Alternatively Spliced Variant of HYAL1 Hyaluronidase: A Negative Regulator of Bladder Cancer

Lokeshwar

Estrella²,

López³

et al. 2006

Cancer Research

View full text Add to dashboard Cite

Tumor cells express HYAL1 hyaluronidase, which degrades hyaluronic acid. HYAL1 expression in bladder cancer cells promotes tumor growth, invasion, and angiogenesis. We previously described five alternatively spliced variants of HYAL1 that encode enzymatically inactive proteins. The HYAL1-v1 variant lacks a 30-amino acid sequence that is present in HYAL1. In this study, we examined whether HYAL1-v1 expression affects bladder cancer growth and invasion by stably transfecting HT1376 bladder cancer cells with a HYAL1-v1 cDNA construct. Although HYAL1-v1 transfectants expressed equivalent levels of enzymatically active HYAL1 protein when compared with vector transfectants, their conditioned medium had 4-fold less hyaluronidase activity due to a noncovalent complex formed between HYAL1 and HYAL1-v1 proteins. HYAL1-v1 transfectants grew 3-to 4-fold slower due to cell cycle arrest in the G 2 -M phase and increased apoptosis. In HYAL1-v1 transfectants, cyclin B1, cdc2/p34, and cdc25c levels were z2-fold lower than those in vector transfectants. The increased apoptosis in HYAL1-v1 transfectants was due to the extrinsic pathway involving Fas and Fas-associated death domain up-regulation, caspase-8 activation, and BID cleavage, leading to caspase-9 and caspase-3 activation and poly(ADP-ribose) polymerase cleavage. When implanted in athymic mice, HYAL1-v1-expressing tumors grew 3-to 4-fold slower and tumor weights at day 35 were 3-to 6-fold less than the vector tumors (P < 0.001). Whereas vector tumors were infiltrating and had high mitoses and microvessel density, HYAL1-v1 tumors were necrotic, infiltrated with neutrophils, and showed low mitoses and microvessel density. Therefore, HYAL-v1 expression may negatively regulate bladder tumor growth, infiltration, and angiogenesis.

show abstract

“…RT-PCR and cDNA cloning, protein purification, immunoblotting, pH activity profile and immunohistochemistry have revealed that HYAL-1 is the major tumor-derived HAase expressed in prostate and bladder carcinoma cells with invasive/metastatic potential (Lokeshwar et al, 1999;Csoka et al, 2001;Lokeshwar et al, 2001;Eissa et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer?

Mammadov

Aslan²,

Tuna³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Molecular prognostic markers have been under investigation for the last decade and no validated marker to date has been proven to be used in daily clinical practice for urinary bladder cancers. The aim of the present study is to evaluate the significance of HYAL-1 expression in prediction of recurrence and progression in pT1 urothelial carcinomas. Materials and Methods: Eighty-nine urothelial carcinoma cases staged as T1 according to 2004 WHO classification were studied. Representative sections from every case were stained immunohistochemically for HYAL-1 and scored between 0 and +3, according to staining density, and graded as low and high for the scores 0-1 and 2-3, respectively. Results: Of the 89 pT1 bladder cancer patients, HYAL-1 expression was high in 92.1% (82 patients; 72 patients +3 and 10 patients +2) and low in 7.9% (only 7 patients; 6 patients +1 and 1 patient 0) of the cases. Of the 89 patients, 38 (42.7%) had recurrence and 22 (24.7%) showed progression. HYAL-1 staining did not show significant characteristics for tumor grade, accompanying CIS, multiplicity, tumor size, age and sex. HYAL-1 expression did not have any prognostic value in estimating recurrence or progression. Conclusions: HYAL-1 expression was found to be high, but did not have any prognostic importance in T1 bladder urothelial carcinomas.

show abstract

Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs

Cited by 53 publications

References 22 publications

The clinical relevance of urine-based markers for diagnosis of bladder cancer

The clinical relevance of urine-based markers for diagnosis of bladder cancer

HYAL1-v1, An Alternatively Spliced Variant of HYAL1 Hyaluronidase: A Negative Regulator of Bladder Cancer

Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer?

Contact Info

Product

Resources

About